Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

136P - Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous NSCLC (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy: An updated analysis

Date

12 Dec 2024

Session

Poster Display session

Presenters

Baohui Han

Citation

Annals of Oncology (2024) 24 (suppl_1): 1-26. 10.1016/iotech/iotech100745

Authors

B. Han1, H. Zhong2, Q. Guo3, P. Tian4, Y. Zhao5, X. Yu6, Z. Yu7, X. Zhang1, Y. Zhang8, Y. Li4, L. Chen5, X. Shi6, J. Wang7

Author affiliations

  • 1 Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/CN
  • 2 Shanghai Chest Hospital, Shanghai Jiao Tong University, 200030 - Shanghai/CN
  • 3 Shandong Cancer Hospital and Institute, 250000 - Jinan/CN
  • 4 West China School of Medicine/West China Hospital of Sichuan University, Chengdu/CN
  • 5 Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou/CN
  • 6 Zhejiang Cancer Hospital, Hangzhou/CN
  • 7 The Affiliated Hospital of Qingdao University, Qingdao/CN
  • 8 Shandong Cancer Hospital and Institute, Jinan/CN

Resources

This content is available to ESMO members and event participants.

Abstract 136P

Background

We conducted a multicenter, open-label, phase 2 study to evaluate TIS + platinum-based chemo (cohort 1) or TIS + mono-chemo + beva (cohort 2) in EGFR-mutated nsq-NSCLC pts who progressed on EGFR TKI therapies. Our previous results showed that both cohorts met the primary endpoint (1-year PFS rate). Here, we report the updated analysis with extended follow-up.

Methods

EGFR-mutated, nsq-NSCLC pts who had failed prior EGFR-TKIs received induction therapy with TIS + carboplatin (CBP) + nab-paclitaxel (nab-P; cohort 1) or TIS + nab-P + beva (cohort 2) every 3 weeks for 4 cycles, followed by maintenance therapy with TIS + pemetrexed (cohort 1) or TIS + beva (cohort 2) for up to 31 cycles.

Results

A total of 123 pts were enrolled (cohort 1, n=69; cohort 2, n=54). As of Aug 2, 2024, minimum study follow-up time (from the last patient’s first dose to data cutoff) was 32.3 and 17.1 mo, respectively for cohort 1 and cohort 2. Median OS was 27.1 mo in cohort 1, and 2-year and 3-year OS rates were 53.5% and 38.2%, respectively. For cohort 2, median OS was not reached, with 2-year OS rate of 61.4%. Pts with EGFR exon 21 L858R mutation had significantly longer OS than those with exon 19 deletion in cohort 1, while no similar trend was observed in cohort 2. Median PFS was 7.6 and 10.3 mo, respectively (Table). After prolonged follow-up, toxicity was manageable, with no new safety signals observed in both cohorts. Table: 136P

Cohort 1 TIS + CBP + nab-P Cohort 2 TIS + nab-P+ beva
Minimum study follow-up time∗, mo 32.3 17.1
Median OS, mo (95% CI) 27.1 (17.5, 36.9) NR (19.2, NE)
OS rate, % (95% CI)
1-year 75.2 (62.2, 84.2) 78.8 (65.1, 87.7)
2-year 53.5 (40.1, 65.1) 61.4 (45.3, 74.1)
3-year 38.2 (24.9, 51.5) NR (NE, NE)
Median PFS, mo (95% CI) 7.6 (5.8, 9.4) 10.3 (6.4, 14.5)
1-year PFS rate, % (90% CI) 25.4 (16.4, 35.3) 42.2 (30, 53.8)

From the last patient’s first dose to data cutoff. NR, not reached; NE, not estimable.

Conclusions

TIS + platinum-based chemo (cohort 1) and TIS + mono-chemo + beva (cohort 2) demonstrated encouraging OS benefits and manageable toxicity for pts with EGFR-mutated nsq-NSCLC after EGFR TKI failure with extended follow-up. This study expands the treatment options for this patient population, allowing clinicians to tailor their choices based on individual patient circumstances.

Clinical trial identification

NCT04405674.

Legal entity responsible for the study

The authors.

Funding

BeiGene Ltd.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.